Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test
- 1 February 2007
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (2) , 169-173
- https://doi.org/10.1136/ard.2006.054866
Abstract
Background: The 6-min walk test (6MWT) is increasingly used as an outcome measure in interstitial lung disease (ILD). Aim: To evaluate the usefulness of the 6MWT in a cohort of patients with ILD secondary to systemic sclerosis (SSc) and to correlate with established physiological parameters. Methods: 163 patients with SSc-ILD were recruited for a multicentre, randomised, double-blind clinical trial. Available data at protocol screening included repeated 6MWTs, pulmonary function testing with diffusing capacity, Doppler echocardiography and high-resolution computed tomography of the thorax. Borg Dyspnoea Index was evaluated before and after 6MWT. Results: Mean (standard deviation (SD)) distance walked during walk test 1 was 396.6 (84.55) m compared with 399.5 (86.28) m at walk test 2. The within-subject, intertest correlation as determined by Pearson’s correlation coefficient testing was 0.95 (pConclusion: These data confirm the high reproducibility of the 6MWT in patients with SSc-ILD and therefore the validity of the test in this cohort. The lack of correlation of 6MWT with standard physiological parameters of ILD suggests a multifactorial basis for limited exercise capacity in patients with SSc and calls into question the utility of the 6MWT as a measure of outcome in future studies on SSc-ILD.Keywords
This publication has 27 references indexed in Scilit:
- Cyclophosphamide versus Placebo in Scleroderma Lung DiseaseNew England Journal of Medicine, 2006
- Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approachAnnals of the Rheumatic Diseases, 2003
- Predictors of end stage lung disease in a cohort of patients with sclerodermaAnnals of the Rheumatic Diseases, 2003
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Comparison of echocardiographic assessment of cardiac hemodynamics in the intensive care unit with right-sided cardiac catheterizationThe American Journal of Cardiology, 1995
- Severe restrictive lung disease in systemic sclerosisArthritis & Rheumatism, 1994
- Mitral regurgitation and diastolic flow profile in systemic sclerosisInternational Journal of Cardiology, 1990
- Non‐invasive assessment of left ventricular diastolic function in patients with systemic sclerosisJournal of Internal Medicine, 1990
- Preliminary criteria for the classification of systemic sclerosis (scleroderma)Arthritis & Rheumatism, 1980